InsightRX Raises $10 Million To Personalize Drug Doses

On September 20, InsightRX, a precision medicine company, announced the closing of a $10 million Series A funding round led by HealthX Ventures with participation from Rock Health, OSF Healthcare, Leawood Venture Capital, Premier Inc. and previous investor GreatPoint Ventures.

Using patient-specific data, quantitative pharmacology models, and what is known as Bayesian forecasting, InsightRX have built software to help clinicians prescribe optimal doses of powerful medications, increasing the likelihood of the most therapeutic benefit with the least side effects. InsightRX’s software is currently in use across more than 100 drug and therapeutic areas, including oncology and infectious diseases and through this approach, hospitals, care teams and patients could realize a number of benefits.

The full Forbes article can be viewed at this link.